IL-12, IFN-γ, and T cell proliferation to measles in immunized infants

Journal of Immunology

Volumn 162, Issue 9, 1999, Pages 5569-5575

  Gans, Hayley A ^a,b   Maldonado, Yvonne ^b   Yasukawa, Linda L ^b   Beeler, Judy ^c   Audet, Susette ^c   Rinki, Mary M ^b   DeHovitz, Ross ^d   Arvin, Ann M ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^d PALO ALTO MEDICAL FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DOWN REGULATION; HUMAN; IMMUNE RESPONSE; INFANT; MEASLES; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

ADULT; AGE FACTORS; ANTIBODIES, VIRAL; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; INFANT; INTERFERON TYPE II; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MEASLES VACCINE; MONOCYTES; NEUTRALIZATION TESTS; PHYTOHEMAGGLUTININS; RECOMBINANT PROTEINS; T-LYMPHOCYTES; VACCINES, ATTENUATED;

EID: 0033136280     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Aaby, P., J. Bukh, D. Kronborg, I. M. Lisse, and M. C. da Silva. 1990. Delayed excess mortality after exposure to measles during the first six mos of life. Am. J. Epidemiol. 132:211.
2. Aaby, P., J. Clements, and V. Orinda. 1991. Mortality from measles: measuring the impact. In Expanded Programme on Immunization. World Health Organization, ed. World Health Organization, Geneva.
3. Clements, C. J., and F. T. Cutts. 1995. The epidemiology of measles: thirty years of vaccination. Curr. Top. Microbiol. Immunol. 191:13.
4. Gindler, J. S., W. L. Atkinson, L. E. Markowitz, and S. S. Hutchins. 1992. Epidemiology of measles in the United States in 1989 and 1990. Pediatr. Infect. Dis. J. 11:841.
5. Griffin, D. E. 1995. Immune responses during measles virus infection. Curr. Top. Microbiol. Immunol. 191:117.
6. Griffin, D. E., B. J. Ward, and L. M. Esolen. 1994. Pathogenesis of measles virus infection: an hypothesis for altered immune responses. J. Infect. Dis. 170(Suppl. 1):S24.
7. Wakeham, P. F. 1978. Severe measles in Afghanistan. J. Trop. Pediatr. Environ. Child Health 24:87.
8. Griffin, D. 1991. Immunologic abnormalities accompanying acute and chronic viral infections. Rev. Infect. Dis. 13(Suppl. 1):S129.
9. Griffin, D. E., and B. J. Ward. 1993. Differential CD4 T cell activation in measles. J. Infect. Dis. 168:275.
10. Ward, B. J., R. T. Johnson, A. Vaisberg, E. Jauregui, and D. E. Griffin. 1991. Cytokine production in vitro and the lymphoproliferative defect of natural measles virus infection. Clin. Immunol. Immunopathol. 61:236.
11. Ward, B. J., and D. E. Griffin. 1993. Changes in cytokine production after measles virus vaccination: predominant production of IL-4 suggests induction of a Th2 response. Clin. Immunol. Immunopathol. 67:171.
12. Smedman, L., A. Joki, A. Jose da Silva, M. Troye-Blomberg, B. Aronsson, and P. Perlmann. 1994. Immunosuppression after measles vaccination. Acta Paediatr. 83:164.
13. Zweiman, B., D. Pappagianis, H. Maibach, and E. A. Hildreth. 1971. Effect of measles immunization on tuberculin hypersensitivity and in vitro lymphocyte reactivity. Int. Arch. Allergy 40:834.
14. Tamashiro, V. G., H. H. Perez, and D. E. Griffin. 1987. Prospective study of the magnitude and duration of changes in tuberculin reactivity during uncomplicated and complicated measles. Pediatr. Infect. Dis. J. 6:451.
15. Starr, H., and S. Berkovich. 1964. Effects of measles, γ-globulin-modified measles and vaccine measles on the tuberculin test. N. Engl. J. Med. 270:386.
16. Hirsch, R. L., D. E. Griffin, R. T. Johnson, S. J. Cooper, I. Lindo de Soriano, S. Roedenbeck, and A. Vaisberg. 1984. Cellular immune responses during complicated and uncomplicated measles virus infections of man. Clin. Immunol. Immunopathol. 31:1.
17. Finkel, A., and P. B. Dent. 1973. Abnormalities in lymphocyte proliferation in classical and atypical measles infection. Cell. Immunol. 6:41.
18. Griffin, D. E., B. J. Ward, E. Jauregui, R. T. Johnson, and A. Vaisberg. 1989. Immune activation in measles. N. Engl. J. Med. 320:1667.
19. Griffin, D. E., B. J. Ward, E. Jauregui, R. T. Johnson, and A. Vaisberg. 1990. Natural killer cell activity during measles. Clin. Exp. Immunol. 81:218.
20. Griffin, D. E., S. J. Cooper, R. L. Hirsch, R. T. Johnson, I. Lindo de Soriano, S. Roedenbeck, and A. Vaisberg. 1985. Changes in plasma IgE levels during complicated and uncomplicated measles virus infections. J. Allergy Clin. Immunol. 76:206.
21. Dorig, R. E., A. Marcil, and C. D. Richardson. 1994. CD46, a primate-specific receptor for measles virus. Trends Microbiol. 2:312.
22. Dunster, L. M., J. Schneider-Schaulies, M. H. Dehoff, V. M. Holers, R. Schwartz-Albiez, and V. ter Meulen. 1995. Moesin, and not the murine functional homologue (Crry/p65) of human membrane cofactor protein (CD46), is involved in the entry of measles virus (strain Edmonston) into susceptible murine cell lines. J. Gen. Virol. 76:2085.
23. Schneider-Schaulies, J., L. M. Dunster, F. Kobune, B. Rima, and V. ter Meulen. 1995. Differential downregulation of CD46 by measles virus strains. J. Virol. 69:7257.
24. Karp, C. L., M. Wysocka, L. M. Wahl, J. M. Aheam, P. J. Cuomo, B. Sherry, G. Trinchieri, and D. E. Griffin. 1996. Mechanism of suppression of cell-mediated immunity by measles virus. Science 273:228.
25. + T lymphocytes. J. Immunol. 155:111.
26. Hendrzak, J. A., and M. J. Brunda. 1995. Interleukin-12: biologic activity, therapeutic utility, and role in disease. Lab. Invest. 72:619.
27. + T cells requires the coordinate action of interleukin-12 and interferon-y and is inhibited by transforming growth factor-β. Eur. J. Immunol. 24:793.
28. Trinchieri, G. 1997. Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN-γ). Curr. Opin. Immunol. 9:17.
29. Scharton-Kersten, T., L. C. Afonso, M. Wysocka, G. Trinchieri, and P. Scott. 1995. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J. Immunol. 154:5320.
30. Heufler, C., F. Koch, U. Stanzl, G. Topar, M. Wysocka, G. Trinchieri, A. Enk, R. M. Steinman, N. Romani, and G. Schuler. 1996. lnterleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as Interferon-γ production by T helper 1 cells. Eur. J. Immunol. 26:659.
31. Chehimi, J., and O. Trinchieri. 1994. Interleukin-12: a bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency. J. Clin. Immunol. 14:149.
32. Siegrist, C.-A., C. Barrios, X. Martinez, C. Brandt, M. Berney, M. Cordova, J. Kovarik, and P.-H. Lambert. 1998. Influence of maternal antibodies on vaccine responses:inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice. Eur. J. Immunol. 28:4138.
33. Siegrist, C. A. 1997. Potential advantages and risks of nucleic acid vaccines for infant immunization. Vaccine 15:798.
34. Martinez, X., C. Brandt, F. Saddallah, C. Tougne, C. Barrios, F. Wild, G. Dougan, P. H. Lambert, and C. A. Siegrist. 1997. DNA immunization circumvents deficient induction of T helper type 1 and cytotoxic T lymphocyte responses in neonates and during early life. Proc. Natl. Acad. Sci. USA 94:8726.
35. Barrios, C., C. Brandt, M. Berney, P. H. Lambert, and C. A. Siegrist. 1996. Partial correction of the TH2/TH1 imbalance in neonatal murine responses to vaccine antigens through selective adjuvant effects. Eur. J. Immunol. 26:2666.
36. Barrios, C., P. Brawand, M. Berney, C. Brandt, P. H. Lambert, and C. A. Siegrist. 1996. Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting. Ear. J. Immunol. 26:1489.
37. Wilkins, J., and P. F. Wehrle. 1979. Additional evidence against measles vaccine administration to infants less than 12 months of age: altered immune response following active/passive immunization. J. Pediatr. 94:865.
38. Siegrist, C. A., and P. H. Lambert. 1997. Immunization with DNA vaccines in early life: advantages and limitations as compared to conventional vaccines. Springer Semin. Immunopathol. 19:233.
39. Albrecht, P., F. A. Ennis, E. J. Saltzman, and S. Krugman. 1977. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J. Pediatr. 91:715.
40. Cutts, F. T., and L. E. Markowitz. 1994. Successes and failures in measles control. J. Infect. Dis. 170(Suppl. I):S32.
41. Gans, H., A. Arvin, J. Galinus, L. Logan, R. DeHovitz, and Y. Maldonado. 1998. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. J. Am. Med. Assoc. 280:527.
42. Krugman, R. D., R. Rosenberg, K. McIntosh, K. Hermann, J. J. Witte, F. A. Ennis, and B. C. Meyer. 1977. Further attenuated live measles vaccines: the need for revised recommendations. J. Pediatr. 91:766.
43. Yeager, A. S., J. H. Davis, L. A. Ross, and B. Harvey. 1977. Measles immunization: successes and failures. J. Am. Med. Assoc. 237:347.
44. Maldonado, Y. A., E. C. Lawrence, R. DeHovitz, H. Hartzell, and P. Albrecht. 1995. Early loss of passive measles antibody in infants of mothers with vaccine-induced immunity. Pediatrics 96:447.
45. Markowitz, L. E., P. Albrecht, P. Rhodes, R. Demonteverde, E. Swint, E. F. Maes, C. Powell, and P. A. Patriarca. 1996. Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination: Kaiser Permanente Measles Vaccine Trial Team. Pediatrics 97: 53.
46. Johnson, C. E., D. R. Nalin, L. W. Chui, J. Whitwell, R. G, Marusyk, and M. L. Kumar. 1994. Measles vaccine immunogenicity in 6-versus 15-month-old infants born to mothers in the measles vaccine era. Pediatrics 93:939.
47. Albrecht, P., K. Herrmann, and G. R. Burns. 1981. Role of virus strain in conventional and enhanced measles plaque neutralization test. J. Virol. Methods 3:251.
48. Ratnam, S., V. Gadag, R. West, J. Burris, E. Oates, F. Stead, and N. Bouilianne. 1995. Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. J. Clin. Microbiol. 33:811.
49. Whittle, H., M. Rowland, G. Mann, W. Lamb, and R. Lewis. 1984. Immunization of 4-6 month old Gambian infants with Edmonston-Zagreb measles vaccine. Lancet 2:834.
50. Sabin, A. B., P. Albrecht, A. K. Takeda, E. M. Ribeiro, and R. Veronesi. 1985. High effectiveness of aerosolized chick embryo fibroblast measles vaccine in seven-month-old and older infants. J. Infect. Dis. 152:1231.
51. Lewis, D., and C. Wilson. 1995. Developmental Immunology and Role of the Host Defenses in Neonatal Susceptibility to Infection. W. B. Saunders, Philadelphia.
52. Burchett, S. K., L. Corey, K. M. Mohan, J. Westall, R. Ashley, and C. B. Wilson. 1992. Diminished interferon-γ and lymphocyte proliferation in neonatal and post-partum primary herpes simplex virus infection. J. Infect Dis. 165:813.
53. Wilson, C. 1986. Immunologic basis of increased susceptibility of the neonate to infection. J. Pediatr. 108.
54. Sullender, W. M., J. L. Miller, L. L. Yasukawa, J. S. Bradley, S. B. Black, A. S. Yeager, and A. M. Arvin. 1987. Humoral and cell-mediated immunity in neonates with herpes simplex virus infection. [Published erratum appears in J. Infect. Dis. 1987 Apr;155:838.] J. Infect. Dis. 155:28.
55. Siegrist, C. A. 1997. Vaccination strategies for children with specific medical conditions: a paediatrician's viewpoint. Eur. J. Pediatr. 156:899.
56. Siegrist, C. A., and P. H. Lambert. 1996. DNA vaccines: what can we expect? Infect. Agents Dis. 5:55.
57. + T cells. Eur. J. Immunol. 24:343.
58. Kennedy, M. K., K. S. Picha, W. C. Fanslow, K. H. Grabstein, M. R. Alderson, K. N. Clifford, W. A. Chin, and K. M. Mohler. 1996. CD40/CD40 ligand interactions are required for T cell-dependent production of interleukin-12 by mouse macrophages. Eur. J. Immunol. 26:370.
59. Markowitz, L., and S. Katz. 1994. Measles Vaccine. W. B. Saunders, Philadelphia.
60. Ward, B. J., N. Boulianne, S. Ratnam, M. C. Guiot, M. Couillard, and G. De Serres. 1995. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J. Infect. Dis. 172:1591.
61. Pass, R. F., M. E. Dworsky, R. J. Whitley, A. M. August, S. Stagno, and C. A. Alford, Jr. 1981. Specific lymphocyte blastogenic responses in children with cytomegalovirus and herpes simplex virus infections acquired early in infancy. Infect. Immun. 34:166.
62. Shelton, J. D., J. E. Jacobson, W. A. Orenstein, K. F. Schulz, and H. D. Donnell, Jr. 1978. Measles vaccine efficacy: influence of age at vaccination vs. duration of time since vaccination. Pediatrics 62:961.
63. Shasby, D. M., T. C. Shope, H. Downs, K. L. Herrmann, and J. Polkowski. 1977. Epidemic measles in a highly vaccinated population. N. Engl. J. Med. 296:585.
64. Schluederberg, A., S. H. Lamm, P. J. Landrigan, and F. L. Black. 1973. Measles immunity in children vaccinated before one year of age. Am. J. Epidemiol. 97: 402.
65. Cults, F. T., B. Nyandu, L. E. Markowitz, T. Forsey, E. R. Zell, O. Othepa, and K. Wilkins. 1994. Immunogenicity of high-titre AIK-C or Edmonston-Zagreb vaccines in 3.5-month-old infants, and of medium-or high-titre Edmonston-Zagreb vaccine in 6-month-old infants, in Kinshasa, Zaire. Vaccine 12:1311.
66. Good, R., and S. Zak. 1956. Disturbances in γ globulin synthesis as "experiments of nature". Pediatrics 18:109.
67. Ruckdeschel, J. C., K. D. Graziano, and M. R. Mardiney, Jr. 1975. Additional evidence that the cell-associated immune system is the primary host defense against measles (rubeola). Cell. Immunol. 17:11.